SLC16A1 and neoplasm: Unfortunately, MCT1 inhibitors are ineffective in tumor cells that highly express MCT4, which suggests that MCT4 expression may serve as a biomarker for patient selection and predictor of response to anti-MCT1 therapy (98, 99).